| scholarly article | Q13442814 |
| P2093 | author name string | Oliver W Press | |
| Yukang Lin | |||
| D Scott Wilbur | |||
| Donald K Hamlin | |||
| Ajay K Gopal | |||
| John M Pagel | |||
| Joseph G Rajendran | |||
| Aimee Kenoyer | |||
| Damian J Green | |||
| Darrell R Fisher | |||
| Steven I Park | |||
| Anastasia Pantelias | |||
| Eneida R Nemecek | |||
| P2860 | cites work | Internal dosimetry for systemic radiation therapy | Q33869348 |
| Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts | Q34762427 | ||
| Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas | Q35828820 | ||
| A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma | Q35848351 | ||
| 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. | Q35849468 | ||
| Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas | Q35849837 | ||
| Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. | Q35924871 | ||
| Human homologue of murine T200 glycoprotein. | Q36344070 | ||
| Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. | Q36445890 | ||
| Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. | Q36787584 | ||
| Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. | Q37036289 | ||
| Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity | Q37118311 | ||
| A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. | Q40296288 | ||
| A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity | Q40702351 | ||
| Treatment approaches to the low-grade lymphomas | Q40716421 | ||
| CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets | Q40983534 | ||
| Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model | Q41647059 | ||
| Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines | Q41746312 | ||
| Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy | Q43625794 | ||
| Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. | Q44031707 | ||
| Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support | Q44080136 | ||
| Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. | Q44225929 | ||
| Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. | Q44350601 | ||
| Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy | Q44594055 | ||
| Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results | Q44870094 | ||
| Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque | Q45104917 | ||
| A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy | Q47807458 | ||
| Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma | Q48010246 | ||
| A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels | Q67720697 | ||
| Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody | Q68052741 | ||
| Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas | Q68812167 | ||
| Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation | Q69506136 | ||
| Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody | Q69520763 | ||
| Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies | Q69522036 | ||
| Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies | Q69660072 | ||
| Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin | Q70290393 | ||
| Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation | Q72529067 | ||
| A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts | Q74595839 | ||
| The use of paired labeling in the determination of tumor-localizing antibodies | Q74642184 | ||
| Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue | Q77435841 | ||
| Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome | Q78102284 | ||
| Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? | Q78948018 | ||
| Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model | Q81383380 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1226-1235 | |
| P577 | publication date | 2009-06-10 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates | |
| P478 | volume | 114 |
| Q37675882 | A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. |
| Q37044940 | A self-assembling short oligonucleotide duplex suitable for pretargeting |
| Q36395999 | Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery |
| Q34039426 | Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF |
| Q57813529 | An Anti-Tumor Immune Response is Evoked By Partial-Volume Single Dose Radiation in Two Murine Models |
| Q37720850 | Antibody vectors for imaging |
| Q35070045 | Cancer radioimmunotherapy |
| Q38799356 | Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers |
| Q35085501 | Comparative quantitative analysis of cluster of differentiation 45 antigen expression on lymphocyte subsets |
| Q28256317 | Mantle cell lymphoma: observation to transplantation |
| Q39129504 | Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle |
| Q34149984 | Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody |
| Q37644054 | Optimising the conditioning regimen for acute myeloid leukaemia |
| Q33771667 | Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms |
| Q52672956 | Pazopanib radio-sensitization of human sarcoma tumors. |
| Q34113941 | Pretargeted radioimmunotherapy for hematologic and other malignancies |
| Q38096058 | Radioimmunotherapy for hematopoietic cell transplantation |
| Q93079994 | Therapeutic Applications of Pretargeting |
| Q36438435 | Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles |
Search more.